You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The public-private partnership has published a paper on a list of indels larger than 50 bp that is already being used to develop new methods.
The company plans to use the funding to finish developing and commercially launch its HD-Mapping whole-genome electronic mapping platform.
The Brown University spinout plans to market its instrument, Nabsys HD-Mapping, for genome mapping, de novo assembly, and structural variant detection.
At a workshop organized by the Genome in a Bottle consortium last month, Nabsys presented its human genome maps for the first time.
After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.
Former CEO Barrett Bready has purchased the recently shuttered Nabsys for $500,000 and the assumption of $100,000 in debt, according to GoLocalProv.
According to local news reports, the company recently closed its facility in Providence, Rhode Island.
Nabsys CEO Steve Lombardi and CSO Tony Shuber spoke with GenomeWeb at last week's JP Morgan conference in San Francisco.
The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.
NabSys has been awarded
Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.